Nov 29, 2021 5:45pm EST Pasithea Therapeutics Corp. Announces Closing of $30.4 Million Private Placement Priced at a Premium to the Market Under Nasdaq Rules
Nov 24, 2021 8:52am EST Pasithea Therapeutics Corp. Announces Pricing of a $30.4 Million Private Placement Priced at a Premium to the Market Under Nasdaq Rules
Nov 23, 2021 8:00am EST Pasithea Therapeutics Adds Esketamine Nasal Spray to its Clinic Offerings in the U.K.
Nov 17, 2021 8:00am EST Pasithea Therapeutics Launches In-Home Intravenous Ketamine Therapy in Major U.S. Cities, Expanding its International Footprint
Nov 11, 2021 8:00am EST Pasithea Therapeutics Collaborates with Renowned Musician and Producer to Create Soundtracks for Ketamine Therapy
Nov 09, 2021 8:00am EST Pasithea Therapeutics Corp. Establishes Scientific Advisory Board and Names Dr. Charles B. Nemeroff as Chair
Oct 27, 2021 7:45am EDT Pasithea Therapeutics Announces Successful Treatment of First Patients in the UK with Ketamine Infusion Therapy
Oct 14, 2021 7:45am EDT Pasithea Therapeutics Opens its First Ketamine Therapy Clinic in the United Kingdom
Oct 11, 2021 6:50am EDT Pasithea Therapeutics Corp. and Evotec SE Enter into Drug Development Agreement
